Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-231A, AD-231B, and AD-231C drug-drug interaction study in healthy volunteers
NCT07312773Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Jan 2026
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AD-231A in hypertension (HTN) and hyperlipidemia (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma concentration-time curve during dosing interval at steady state at Day 14 and Maximum concentration of drug in plasma at steady state at Day 14. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
AD-231A
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT07312773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07312773.